DCRI-collaboration-empact-mi

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin ’s effects following an acute myocardial infarction Ischemic heart disease, including myocardial infarction, is the leading cause of death in the world1EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetesThe trial is part of the EMPOWER clinical trial program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic conditions   
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news

Related Links:

Int J Biochem Cell Biol. 2021 Sep 17:106076. doi: 10.1016/j.biocel.2021.106076. Online ahead of print.ABSTRACTIschemic heart disease promotes complex inflammatory and remodelling pathways which contribute to the development of chronic heart failure. Although blood-derived and local cardiac mediators have traditionally been linked with these processes, the pericardial space has more recently been noted as alternative contributor to the injury response in the heart. The pericardial space contains fluid rich in physiologically active mediators, and immunologically active adipose tissue, which are altered during myocardial inf...
Source: The International Journal of Biochemistry and Cell Biology - Category: Biochemistry Authors: Source Type: research
Am J Manag Care. 2021 Sep 1;27(9):e293-e300. doi: 10.37765/ajmc.2021.88741.ABSTRACTOBJECTIVES: High-sensitivity troponin T (hsTnT) testing was approved in the United States to better facilitate diagnosis of acute coronary syndrome (ACS). Although hsTnT has been widely studied internationally, the impact of hsTnT on discharge diagnoses and health care utilization within the United States is less known. We sought to evaluate the effects of implementing hsTnT on diagnosis patterns and stress testing utilization.STUDY DESIGN: We performed a retrospective cohort analysis consisting of patients with suspected ACS undergoing eith...
Source: The American Journal of Managed Care - Category: Health Management Authors: Source Type: research
Pronounced differences between the sexes have been widely demonstrated in cardiovascular diseases, as well as the response to therapy [1]. For example, men and women develop different types of ischaemic heart disease (IHD), with men suffering more frequently from occlusive coronary artery disease (CAD), while women present more frequently with non-obstructive coronary arteries. The sex-biased pathophysiology of IHD, along with differences in age and comorbidities, contributes to significant sex differences in the onset, presentation and outcome of myocardial infarction (MI), as well as the risk of heart failure (HF) following MI.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate canc...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
In this study, data analysis was performed on 52 patients. According to the different outcomes and discharge diagnosis of patients, data on sedative use, emotions, behavioral abnormalities, hearing loss, pain, total time on board the IABP (intra-aortic balloon pumping), and days of hospitalization of patients were collected. The data were subjected to frequency analysis, paired chi-square analysis, chi-square test, Poisson regression analysis, and stepwise regression analysis. Some findings of the analysis included the following: Between outcome and admission diagnosis, the analysis showed that significant differences exis...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Authors: Source Type: research
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
This study suggested that offsp ring of long-lived siblings not only show lower CVD incidence but also a better survival following CVD diagnosis compared to matched population controls. The higher biological resilience appears to be a universal hallmark of longevity-enriched families, which makes them uniquely positioned for study ing healthy aging and longevity mechanisms.
Source: European Journal of Ageing - Category: Geriatrics Source Type: research
In conclusion, cancer survivors, especially older individuals, demonstrate greater odds of and accelerated functional decline, suggesting that cancer and/or its treatment may alter aging trajectories. Linking Particulate Air Pollution and Dementia in a Small Region of the US https://www.fightaging.org/archives/2021/08/linking-particulate-air-pollution-and-dementia-in-a-small-region-of-the-us/ It is fairly settled that evident particulate air pollution, such as daily exposure to smoke from wood-fueled cooking fires, has a strongly detrimental effect on long-term health. The mechanisms involved are inflamm...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Basic Res Cardiol. 2021 Aug 11;116(1):48. doi: 10.1007/s00395-021-00887-3.ABSTRACTMetabolic modulation is a promising therapeutic approach to prevent adverse remodeling of the ischemic heart. Because little is known about the involvement of long non-coding RNAs (lncRNAs) in regulating cardiac metabolism, we used unbiased transcriptome profiling in a mouse model of myocardial infarction (MI). We identified a novel cardiomyocyte-enriched lncRNA, called LncHrt, which regulates metabolism and the pathophysiological processes that lead to heart failure. AAV-based LncHrt overexpression protects the heart from MI as demonstrated ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
More News: Cardiology | Clinical Trials | Empagliflozin | Endocrinology | Heart | Heart Attack | Heart Disease | Heart Failure | Jardiance | Research | SGLT2 Inhibitors